About Glycerate kinase
Glycerate kinase (GLYCTK) is a protein
from Homo sapiens identified by UniProt accession
Q8IVS8, 523 residues long.
MolForge cross-references it against 0 known binders and
101 disease associations.
Target properties
| Protein name | Glycerate kinase |
| UniProt accession | Q8IVS8 |
| Gene | GLYCTK |
| Organism | Homo sapiens |
| Length | 523 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (101)
Diseases linked to this target (Open Targets).
- D-glyceric aciduria · score 0.72
- total blood protein measurement · score 0.23
- platelet count · score 0.23
- schizophrenia · score 0.17
- blood protein measurement · score 0.16
- platelet crit · score 0.15
- calcium measurement · score 0.15
- cystatin C measurement · score 0.15
- BMI-adjusted waist-hip ratio · score 0.14
- BMI-adjusted waist circumference · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IVS8-F1 | alphafold | PREDICTED | 90.32 | — |
Amino-acid sequence (523 residues)
MAAALQVLPR LARAPLHPLL WRGSVARLAS SMALAEQARQ LFESAVGAVL PGPMLHRALS LDPGGRQLKV RDRNFQLRQN LYLVGFGKAV LGMAAAAEEL LGQHLVQGVI SVPKGIRAAM ERAGKQEMLL KPHSRVQVFE GAEDNLPDRD ALRAALAIQQ LAEGLTADDL LLVLISGGGS ALLPAPIPPV TLEEKQTLTR LLAARGATIQ ELNTIRKALS QLKGGGLAQA AYPAQVVSLI LSDVVGDPVE VIASGPTVAS SHNVQDCLHI LNRYGLRAAL PRSVKTVLSR ADSDPHGPHT CGHVLNVIIG SNVLALAEAQ RQAEALGYQA VVLSAAMQGD VKSMAQFYGL LAHVARTRLT PSMAGASVEE DAQLHELAAE LQIPDLQLEE ALETMAWGRG PVCLLAGGEP TVQLQGSGRG GRNQELALRV GAELRRWPLG PIDVLFLSGG TDGQDGPTEA AGAWVTPELA SQAAAEGLDI ATFLAHNDSH TFFCCLQGGA HLLHTGMTGT NVMDTHLLFL RPR
Explore Glycerate kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets